<bill session="117" type="h" number="6431" updated="2023-03-08T19:58:48Z">
  <state datetime="2022-01-19">REFERRED</state>
  <status>
    <introduced datetime="2022-01-19"/>
  </status>
  <introduced datetime="2022-01-19"/>
  <titles>
    <title type="display">Data Transparency and Drug Safety Act of 2022</title>
    <title type="short" as="introduced">Data Transparency and Drug Safety Act of 2022</title>
    <title type="official" as="introduced">To amend the Federal Food, Drug, and Cosmetic Act to prohibit the alteration, falsification, fabrication, destruction, omission, or removal of records or certain information required to be produced or maintained for a drug, and for other purposes.</title>
  </titles>
  <sponsor bioguide_id="S001216"/>
  <cosponsors>
    <cosponsor bioguide_id="J000302" joined="2022-01-19"/>
  </cosponsors>
  <actions>
    <action datetime="2022-01-19">
      <text>Introduced in House</text>
    </action>
    <action datetime="2022-01-19" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
    <action datetime="2022-01-20">
      <text>Referred to the Subcommittee on Health.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSIF" name="House Energy and Commerce" subcommittee="" activity="Referral"/>
    <committee code="HSIF14" name="House Energy and Commerce" subcommittee="Health" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Health"/>
  </subjects>
  <amendments/>
  <summary date="2022-09-06T18:32:18Z" status="Introduced in House">Data Transparency and Drug Safety Act of 2022

This bill makes it a prohibited act under the Federal Food, Drug, and Cosmetic Act to destroy or falsify certain records pertaining to drugs regulated by the Food and Drug Administration (FDA).

Specifically, the bill prohibits falsifying, destroying, omitting. or removing records or information that (1) must be produced during the development or manufacture of a drug, (2) must be produced in an application for FDA approval for a drug or maintained after a drug is approved, or (3) is subject to FDA inspection.

A person (entity or individual) that violates this provision shall be subject to civil monetary penalties. The bill also provides for additional monetary penalties in instances where the violation is not sufficiently remedied after the responsible person has received written notice from the FDA of the violation.</summary>
</bill>
